Armstrong David A, Soucy Shannon M, Muse Meghan E, Kolling Fred W, Trask Heidi W, Howell Alexandra L, Laue Hannah E, Hoen Anne G, Gui Jiang, Christensen Brock C, Madan Juliette C, Karagas Margaret R, Howe Caitlin G
bioRxiv. 2025 Apr 3:2025.04.01.646630. doi: 10.1101/2025.04.01.646630.
MicroRNAs (miRNAs) are increasingly being investigated as potential biomarkers for child development and disease. Although a growing number of studies are utilizing infant and toddler stool for transcriptomic analyses, no studies have compared protocols for preserving and extracting miRNAs from this specimen type, despite unique challenges, including abundant levels of RNAses and microbial RNA.
To address this, we first compared three commercially available kits and four preservation methods for their ability to yield high quality RNA from infant and toddler stool (Phase 1). RNA quality was determined by fragment analyzer.
Of the three RNA extraction kits compared, Zymo BIOMICs yielded the highest overall RNA Quality Number (RQN) (median (range) RQN 9.4 (5.7-10.0)). Of the four preservation methods tested, stool collected in RNAlater and Zymo DNA/RNA Shield Fecal Collection Tubes yielded the highest two RQNs (median (range) RQN 9.8 (5.7-10.0) and 9.4 (5.4-10.0), respectively), which did not differ significantly from each other ( = 0.47). Second, using miRNA-seq we directly compared miRNA profiles for RNA extracted using the Zymo BIOMICs kit from paired aliquots of the same stool sample from four infants collected into RNAlater and Zymo DNA/RNA Shield Fecal Collection Tubes (Phase 2). Given that microbial sequences greatly outnumber human miRNAs in stool, reads were first classified as human versus microbial prior to aligning human-classified reads to miRBase v22.1. The percentage of reads classified as human and the percentage of human reads aligning to miRBase did not differ for samples collected in RNAlater versus Zymo Shield ( = 0.12 and = 0.86, respectively). Furthermore, after multiple testing correction, normalized miRNA counts did not differ significantly between the two preservatives for any of the 42 human miRNAs detected across the eight samples.
Collecting infant and toddler stool in either RNAlater or Zymo DNA/RNA Shield Fecal Collection Tubes, when paired with RNA extraction using the Zymo BIOMICs extraction kit, yielded high-quality RNA with similar human miRNA profiles. Moreover, of the 42 miRNAs that were detected, several (i.e., miR-194a-3p, miR-200c-3p, miR-26a-5p) are thought to contribute to overall gut homeostasis. These findings may inform protocols for future studies that aim to profile miRNAs in infant and toddler stool to evaluate their potential utility as biomarkers for children's health.
微小RNA(miRNA)作为儿童发育和疾病的潜在生物标志物,正受到越来越多的研究。尽管越来越多的研究利用婴幼儿粪便进行转录组分析,但尚无研究比较从这种样本类型中保存和提取miRNA的方案,尽管存在独特的挑战,包括大量的核糖核酸酶和微生物RNA。
为解决这一问题,我们首先比较了三种市售试剂盒和四种保存方法从婴幼儿粪便中提取高质量RNA的能力(第一阶段)。通过片段分析仪测定RNA质量。
在比较的三种RNA提取试剂盒中,Zymo BIOMICs试剂盒产生的总体RNA质量数(RQN)最高(中位数(范围)RQN 9.4(5.7 - 10.0))。在测试的四种保存方法中,保存在RNAlater和Zymo DNA/RNA Shield粪便收集管中的粪便产生的RQN最高(中位数(范围)分别为RQN 9.8(5.7 - 10.0)和9.4(5.4 - 10.0)),两者之间无显著差异(P = 0.47)。其次,使用miRNA测序,我们直接比较了使用Zymo BIOMICs试剂盒从收集到RNAlater和Zymo DNA/RNA Shield粪便收集管中的四名婴儿的同一份粪便样本的配对等分试样中提取的RNA的miRNA谱(第二阶段)。鉴于粪便中微生物序列的数量大大超过人类miRNA,在将人类分类的读数与miRBase v22.1比对之前,先将读数分类为人类或微生物。保存在RNAlater和Zymo Shield中的样本,分类为人类的读数百分比以及与miRBase比对的人类读数百分比没有差异(分别为P = 0.12和P = 0.86)。此外,经过多重检验校正后,在八个样本中检测到的42种人类miRNA中的任何一种,两种防腐剂之间的标准化miRNA计数均无显著差异。
当与使用Zymo BIOMICs提取试剂盒进行RNA提取配对时,将婴幼儿粪便收集在RNAlater或Zymo DNA/RNA Shield粪便收集管中,可产生具有相似人类miRNA谱的高质量RNA。此外,在检测到的42种miRNA中,有几种(即miR - 194a - 3p、miR - 200c - 3p、miR - 26a - 5p)被认为有助于维持整体肠道稳态。这些发现可能为未来旨在分析婴幼儿粪便中miRNA以评估其作为儿童健康生物标志物的潜在效用的研究方案提供参考。